Cardiac arrest from acquired long QT syndrome: A case report

Heart and Lung: Journal of Acute and Critical Care

Volumn 38, Issue 3, 2009, Pages 238-242

  Kozik, Teri M ^a,b   Wung, Shu Fen ^b  

^a Saint Mary's   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; ESCITALOPRAM; FLUOXETINE; MAGNESIUM SULFATE; TEMAZEPAM; TRAZODONE;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; ARTIFICIAL VENTILATION; CASE REPORT; COMA; DEFIBRILLATION; ELECTROCARDIOGRAM; FEMALE; HEART ARREST; HEART VENTRICLE FIBRILLATION; HUMAN; INTUBATION; LONG QT SYNDROME; PRIORITY JOURNAL; SINUS RHYTHM; SINUS TACHYCARDIA; CHEMICALLY INDUCED; COMPLICATION; FATALITY; MIDDLE AGED; NURSING; POLYPHARMACY; RISK FACTOR;

FATAL OUTCOME; FEMALE; HEART ARREST; HUMANS; LONG QT SYNDROME; MIDDLE AGED; POLYPHARMACY; RISK FACTORS;

EID: 66149149427     PISSN: 01479563     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2008.08.002     Document Type: Article

References (32)

1. Mank-Seymour A.R., Richmond J.I., Wood L.S., Reynolds J.M., Fan Y.T., Warnes G.R., et al. Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes. Am Heart J 152 (2006) 1116-1122
2. LaPointe N.M., Curtis L.H., Chan K.A., Kramer J.M., Lafata J.E., Gurwitz J.H., et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf 15 (2006) 361-368
3. Kunkler K. Acquired long QT syndrome: risk assessment, prudent prescribing and monitoring, and patient education. J Am Acad Nurse Pract 14 (2002) 382-389
4. Justo D., and Zeltser D. Torsades de pointes induced by antibiotics. Eur J Intern Med 17 (2006) 254-259
5. Aslam A.F., Aslam A.K., Vasavada N.C., and Khan I.A. Hypothermia: evaluation, electrocardiographic manifestations, and management. Am J Med 119 (2006) 297-301
6. Al-Khatib S.M., LaPointe N.M., Kramer J.M., and Califf R.M. What clinicians should know about the QT interval. JAMA 289 (2003) 2120-2127
7. Lankipalli R.S., Zhu T., Guo D., and Yan G.-X. Mechanisms underlying arrhythmogenesis in long QT syndrome. J Electrocardiol 38 (2005) 69-73
8. Cubeddu L.X. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 106 (2003) 452-457
9. Owens R.C. QT prolongation with antimicrobial agents. Drugs 64 (2004) 1091-1124
10. Tisdale J.E., Kovacs R., Mi D., MoCabe G.P., Cariera B.L., Sharma N., et al. Accuracy of uncorrected versus corrected QT interval for prediction of torsades de pointes associated with intravenous haloperidol. Pharmacotherapy 27 (2007) 175-182
11. Karjalainen J., Viitasalo M., Manttari M., and Manninen V. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 23 (1994) 1547-1553
12. Milne J.R., Ward D.E., Spurrell R.A., and Camm A.J. The ventricular paced QT interval-the effects of rate and exercise. Pacing Clin Electrophysiol 5 (1982) 352-358
13. Moss A.J., Zareba W., Benhorin J., Coudere J.P., Kennedy H., Locati-Heilbron E., et al. ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Ann Noninvasive Electrocardiol 6 (2001) 333-341
14. Sommargren C.E., and Drew B.J. Preventing torsades de pointes by careful cardiac monitoring in hospital settings. AACN Adv Crit Care 18 (2007) 285-293
15. Darpo B., Nebout T., and Sager P.T. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use E14 Guideline. J Clin Pharmacol 46 (2006) 498-507
16. Darpo B., Agin M., Kazierad D.J., Layton G., Muirhead G., Gray P., et al. Man versus machine: is there an optimal method for QT measurements in thorough QT studies?. J Clin Pharmacol 46 (2006) 598-612
17. Kelly H.G., Fay J.E., and Lavery S.G. Thioridazine hydrochloride (Mellaril): its effects on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 89 (1963) 546-554
18. Curtis L.H., Ostegye T., Sendersky V., Hutchison S., Allen LaPointe N.M., Al-Khatib S.M., et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 114 (2003) 135-141
19. Sala M., Vicentini A., Brambilla P., Montomoli C., Jogia J.R., Caverzasi E., et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 4 (2005) 1-6
20. Thomas D., Gut B., Wendt-Nordahl G., and Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300 (2002) 543-548
21. Tarantino P., Appleton N., and Lansdell K. Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol 510 (2005) 75-85
22. Winkler D., Ortner R., Pirek E., Aschauer H., and Kasper S. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol 21 (2006) 61-62
23. Burgess C.D., Hames T.K., and George C.F. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol 23 (1982) 417-421
24. Rajamani S., Eckhardt L.L., Valdivia C.R., Klemens C.A., Gillman B.M., Anderson C.L., et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149 (2006) 481-489
25. Pacher P., and Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr Pharm Des 10 (2004) 2463-2475
26. Park K.S., Kong I.D., Park K.C., and Lee J.W. Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Med J 40 (1999) 144-151
27. Roden D.M., and Viswanathan P.C. Genetics of acquired long QT syndrome. J Clin Invest 115 (2005) 2025-2032
28. Drew B.J., Califf R.M., Funk M., Kaufman E.S., Krucoff M.W., Laks M.M., et al. Practice standards for electrocardiographic monitoring in hospital settings. An American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young. Circulation 110 (2004) 2721-2746
29. Drew B., and Funk M. Practice standards for ECG monitoring in hospital settings: executive summary and guide for implementation. Crit Care Nurs Clin N Am 18 (2006) 157-168
30. Drew B.J. Pulling it all together. AACN Adv Crit Care 18 (2007) 305-317
31. Viskin S. Long QT syndromes and torsades de pointes. Lancet 354 (1999) 1625-1633
32. Vincent G.M. Prevention of drug-induced long QT syndrome: gender, chemistry, and education. J Cardiovasc Electrophysiol 12 (2001) 546-547